These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12198933)

  • 1. [Difficult standpoints to be taken by the committee of costs and subsidies].
    Persson U; Anell A; Jendteg S
    Lakartidningen; 2002 Jul; 99(30-31):3128-9. PubMed ID: 12198933
    [No Abstract]   [Full Text] [Related]  

  • 2. [Health economic evaluation of recommended drug treatment].
    Jendteg S; Persson U; Anell A
    Lakartidningen; 2002 Jul; 99(30-31):3130-1. PubMed ID: 12198934
    [No Abstract]   [Full Text] [Related]  

  • 3. [Priorities by the board of drug benefits--guidelines clarify. Clinical trials are not sufficient for decisions on subsidizing].
    Carlsson P
    Lakartidningen; 2003 Jul; 100(30-31):2428-9. PubMed ID: 12914137
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evidence-based health care requires knowledge of cost-effectiveness].
    Carlsson P
    Lakartidningen; 2002 Jul; 99(30-31):3122-6. PubMed ID: 12198932
    [No Abstract]   [Full Text] [Related]  

  • 5. [What does the individual patient cost? CPP--the Cost Per Patient method--is the answer].
    Heurgren M; Nilsson H; Erlö C; Sjöli P
    Lakartidningen; 2003 Oct; 100(42):3312-5. PubMed ID: 14619041
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug costs should be based on health economic benefits. A new law on drug benefits requires studies of health economic effects].
    Berggren F
    Lakartidningen; 2003 Jul; 100(30-31):2446-8. PubMed ID: 12914141
    [No Abstract]   [Full Text] [Related]  

  • 12. The Nurse-Family Partnership: a policy priority. In-home nurse visits are cost-effective and evidence based.
    Hill P; Uris P; Bauer T
    Am J Nurs; 2007 Nov; 107(11):73-5. PubMed ID: 18075359
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug utilization decisions should be based on cost-benefit data].
    Bengt J; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Apr 18-24; 102(16):1264-5; discussion 1265. PubMed ID: 15921102
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
    Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J
    Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
    Anlauf M; Hense HW
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
    Jönsson L; Borgström F; Zethraeus N
    Ugeskr Laeger; 2003 Oct; 165(43):4112-6. PubMed ID: 14619061
    [No Abstract]   [Full Text] [Related]  

  • 19. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments].
    Liedholm H; Linné AB
    Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.